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Objective: Treatment-resistance schizophrenia occurs in 20-30% of patients. Clozapine is the 
only medication proven effective for treatment-resistant schizophrenia. However, less than 25% 
of treatment-resistant schizophrenia patients receive clozapine in most settings. Therefore, this 
study was conducted to identify facilitators and barriers to clozapine use, to inform development 
of interventions to maximize appropriate clozapine-utilization. 
 
Methods: Seventy semi-structured phone interviews were conducted with five high- and five 
low-utilization VA Medical Centers, from different US regions including urban and rural areas. 
Interviewees were key informants of clozapine processes, including mental health leadership, 
psychiatrists, clinical pharmacists and advanced practice nurses. Interviews were analyzed 
using an emergent thematic strategy to identify barriers and facilitators to clozapine prescribing.  
 
Results: Key elements associated with high-utilization included integration of non-physician 
psychiatric providers and clear organizational processes and infrastructure for treatment of 
severe mental illness (e.g.  clozapine clinics, larger mental health intensive case management 
services). Low-utilization was associated with lack of champions to support clozapine processes 
and limited-capacity care systems. Obstacles identified at both high- and low-utilization sites 
included complex time-consuming paperwork, reliance on few individuals to facilitate processes, 
and issues related to transportation for patients living far from care facilities.  
 
Conclusions: Implementation efforts to organize, streamline and simplify clozapine processes, 
development of a multidisciplinary clozapine clinic, increasing the size and capacity of existing 
clinics, and provision of transportation are reasonable targets to increase clozapine utilization.  
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Schizophrenia is one of the most disabling disorders. Although effective treatment is available, 
20-30% of patients fail to respond to at least two antipsychotic medications, and are deemed to 
have treatment-resistant schizophrenia.1  Clozapine has been proved superior to other 
antipsychotics for treatment-resistant schizophrenia.2-4 Accordingly, evidence-based treatment-
guidelines and Veterans Affairs (VA) policies agree that patients who do not respond to 
adequate trials of two antipsychotics should be offered clozapine.5-10 However, clozapine is 
associated with side effects including significant weight gain, diabetes and myocarditits.11,12 
Clozapine is also subject to an FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) 
program due to the risk of agranulocytosis. Monitoring requirements vary but many countries 
have similar requirements making this study relevant across healthcare systems. The FDA 
REMS program requires registration of the physician, patient and pharmacy, and frequent 
monitoring and reporting of white blood cell and absolute neutrophil counts (ANC), although the 
reporting of the ANC alone is now required.11,12 Thus, clozapine is both uniquely effective and 
uniquely inconvenient, leading to an imperative to use it as much as possible, combined with a 
“bother” factor that induces clinicians to avoid its use. Therefore, clozapine underutilization may 
persist on the clinician side, in part, due to the increased prescribing complexity compared with 
other antipsychotics. However, clozapine-utilization rates vary between facilities, suggesting it is 
possible to achieve higher clozapine-utilization rates despite these challenges.13-14  
 
Because clozapine is prescribed for a small minority of patients most treatment-resistant 
schizophrenia patients receive less effective antipsychotics.13-16 Another concern is the 
substitution of clozapine with supra-therapeutic antipsychotic doses and polypharmacy of non-
clozapine antipsychotics, strategies generally found to be less effective than 
clozapine.13,16,17,18,19 Thus, by under-using clozapine, the most vulnerable patients are being 
prescribed less effective treatment. It therefore seems worthwhile to consider how clozapine use 
might be increased, despite the known challenges.  
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While there is no consensus on what proportion of patients should be treated with clozapine, all 
treatment refractory patients should be offered clozapine unless there is an absolute 
contraindication (e.g. history of myocarditis or clozapine-induced agranulocytosis).20 Since up to 
30% of patients have treatment-resistant schizophrenia and recognizing that not all patients are 
appropriate candidates or willing to take clozapine, one could estimate clozapine-utilization 
should approach 20% of patients with schizophrenia. Indeed, one study reported 69% of 
patients with treatment-resistant schizophrenia, roughly 20% of all patients with schizophrenia, 
accepted clozapine treatment when offered. However, clozapine-utilization rates of less than 5% 
are reported in multiple settings.13,14,18-20 While the challenges of the clozapine REMS and the 
side effect profile undoubtedly contribute to low-utilization, nationwide VA data indicate some 
sites approach 20% utilization, despite these challenges.15 Thus, low-utilization rates may not lie 
solely in patient refusal or contraindications to clozapine.   
 
Therefore, we conducted a qualitative study to identify facilitators and barriers to clozapine use 
in the VA, at sites with the highest- and lowest clozapine-utilization. This focus on outlier sites 
has the potential to help identify strategies that are both effective and at least moderately 
feasible, since some sites have already succeeded in adopting them.21-13 This in turn can help 
inform a feasible and effective strategy for implementing changes to improve clozapine-
utilization. 
 
METHODS 
Conceptual Model: The Consolidated Framework for Implementation Research (CFIR)  and an 
emergent thematic analysis strategy were used to inform our research and to develop interview 
guides and for high- and low-utilization sites.24-29 CFIR is composed of five domains: intervention 
characteristics, outer-setting, inner-setting, characteristics of individuals involved, and process 
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of implementation as well as 39 constructs and sub-constructs to identify and track barriers and 
facilitators to change in complex medical systems.27,28 Framing the research with CFIR assisted 
in designing and conducting a rigorous assessment of organizational characteristics of sites.29 
 
Study Sites:  Using FY2013 VA prescribing data, facility-level clozapine-utilization rates were 
calculated for patients with schizophrenia or schizoaffective disorder receiving clozapine at each 
VA facility. The denominator was the total number of patients at the site with a diagnosis of 
schizophrenia or schizoaffective disorder (ICD-9 code 295.x), and the numerator was the 
proportion of these patients who received clozapine from a VA pharmacy during FY13. Using 
this definition, clozapine-utilization across the entire VA system was 4%. Five high- and 5 low-
utilization sites were requested to participate. Sites with non-zero rates of utilization were 
contacted, as personnel at sites with zero-utilization might not be able to contribute useful 
information. Sites were generally of different sizes, geographic regions, etc. This was easier to 
accomplish with low-outliers due to the many sites fitting that description. Sites were not 
informed of their utilization status. 
 
Key  Informants:  Purposeful and chain-referral sampling approaches were used to identify 
participants with expertise related to clozapine prescribing, policy and practice.30,31 The Chief of 
Psychiatry was contacted at each site to identify potential participants. Potential participants 
identified by the Chief were contacted to request their participation and to ask them to identify 
potential participants involved in local clozapine policies, processes and prescribing (chain-
referral sampling). Chain referral sampling was also used to confirm interview subjects were 
considered experts on clozapine policy and practice by staff.32,33 Participants were divided into 
leadership figures and front-line clinicians. Leadership figures may not directly prescribe or 
manage clozapine, but are involved in creating, influencing or implementing policies or 
managing departments integral to clozapine processes (i.e. laboratory, information technology, 
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psychiatry and pharmacy). Front-line clinicians were directly responsible for prescribing or 
managing patients receiving clozapine (i.e. psychiatrists, advanced practice nurses, clinical 
pharmacists).  
 
Interviews:  Semi-structured telephone interviews were conducted between September 2014 
and May 2015. Participants provided informed consent prior to the interview. Interview guides 
were informed by CFIR and relevant literature.27,28 Interviews focused on perceptions of 
clozapine risks and benefits, local and national clozapine policies and processes (formal and 
informal), departmental interfaces regarding clozapine-utilization, sources of clozapine policies 
and procedures, and patient perceptions of clozapine.  
 
Data  Analysis:  Coding and analysis of interview transcripts was completed by experts in 
qualitative research methods (RE and MM) and experts in medicine and psychiatry with 
qualitative research experience (JG and AR). All coders conducted interviews. The codebook 
was developed using inductively-informed grounded thematic analysis.24-26 The finalized 
codebook identified broad themes relating to “domains” regarding clozapine beliefs, policies, 
practices and processes. Once the codebook was finalized, interrater consensus was reached 
through an iterative process with four interviews coded by all four team members. The 
remaining interviews were coded by one investigator except for two interviews coded by all four 
to ensure continued inter-rater reliability. Each investigator coded interviews from different sites 
and job roles. Next each facility was assigned to one investigator, who independently reviewed 
all coded interviews for that site and synthesized data into a profile of that site’s organizational 
structure, clozapine management policies and procedures, and beliefs related to clozapine. 
Thus interviewee data was triangulated so provider perceptions of individual and organizational 
structures and processes of care could be analyzed and contextualized within site and across 
sites. Quote tables containing representative quotes from sites were developed for each 
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domain. Finally, looking across site profiles, the team identified thematic domains that defined 
the differences between high- and low-utilization sites. All data were coded and analyzed using 
NVivo 10. 
This study was approved by Edith Nourse Rogers Memorial Veterans Hospital, Bedford, 
Massachusetts Institutional Review Board.  
 
RESULTS 
Seventy interviews were conducted five sites in the top 10% for clozapine-utilization (> 8% of all 
patients with schizophrenia) and five sites with lower than median utilization (< 4%) (Tables 
1&2).   
 
Five thematic domains related to clozapine-utilization were identified. (Table 3) Domains were 
conceptualized based on potential to develop interventions unique to each domain. Each 
domain is discussed in detail below, with Table 4 providing representative quotes from each 
domain. 
 
Transportation:  The most pervasive issue was patients’ needs and resources related to 
transportation for weekly visits and laboratory monitoring. Lack of reliable transportation was 
mentioned by low- and high-utilization sites, even at sites located in environments with adequate 
public transportation. Reasons cited included disorganized patients’ inability to navigate public 
transit, patients too paranoid to ride public transit, and cost of transportation. Patients living far 
from care facilities were not considered clozapine candidates, regardless of clinical need, because 
of perceptions patients could not attend weekly visits. Sites with higher clozapine-utilization often 
had greater availability of transportation services (e.g. van to bring patients to appointments).  
Transportation services were often located within mental health intensive case management 
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(MHICM) services; while all sites had MHICM, more clozapine patients were enrolled in MHICM at 
high-utilization sites. However, even high-utilization sites struggled to provide clozapine for 
patients living far from care. 
 
Capacity: Clozapine prescription requires multiple administrative processes including 
registration of physician, patient, and pharmacy, review of informed consent, and weekly visits. 
Thus, there must be adequate clinician availability to accommodate increased visit frequency 
and complete required paperwork, processes, monitoring and reporting. Low-utilization sites 
cited increased prescriber burden as a primary barrier to clozapine-utilization. 
 
Both high- and low-utilization sites expressed concerns over capacity to accommodate 
increased prescribing burden associated with clozapine. Even among high-utilization sites, only 
three achieved clozapine prescribing rates above 10%. Low-utilization sites reported limited 
capacity prevented meaningful clozapine use. High-utilization sites often reported the clozapine 
clinic was functioning at or above capacity. 
 
Multi-disciplinary teams: From analysis of capacity it was clear that a related but independent 
thematic domain was the issue of multi-disciplinary teams. In this theme data were captured and 
analyzed on the use of non-physician providers as well as the gaps and strains at sites that relied 
solely on physicians.  
 
High-utilization sites addressed capacity issues in part through integration of non-physician staff 
into the clozapine team. Advanced practice nurses and clinical pharmacists completed clozapine 
related tasks (e.g. registration, ordering and monitoring laboratories, evaluating side). Low-
utilization sites relied on physicians to complete these tasks. Low-utilization sites expressed the 
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need for more clinical pharmacists in mental health care in general, but especially to facilitate 
the clozapine use.  
 
Care Coordination: While all providers are required to follow the REMS monitoring parameters, 
the process of care was significantly different at high- and low-utilization sites. For example, 
high-utilization sites often had a clearly defined point person or clinic system to organize clozapine 
care.  Multiple entities, including the clozapine registry, psychiatry, laboratory, and pharmacy, all 
play a role in clozapine prescription, necessitating considerable coordination among departments 
and often with the patient or patient’s family. In addition, these steps must happen in a specific 
sequence within narrow timelines. High-utilization sites addressed these issues through 
development of clozapine clinics to coordinate care. Clozapine clinics were largely defined by the 
presence of multi-disciplinary teams, adequate time to accommodate increased visit frequency 
and dedicated support staff. Clozapine clinics were seen as integral to providing clozapine care, 
with high-utilization sites unable to imagine providing clozapine without a clozapine clinic.  
 
While having a clozapine clinic was beneficial, it still limited patient access. Once the capacity of a 
clinic was reached, a decision would need to be made to expand the clinic, often by adding an 
additional session requiring allocation of resources or having additional patients treated outside 
the clinic, meaning a much greater burden for physicians. 
 
Maintaining adequate psychiatric staff is an ongoing issue for many facilities, but particularly for 
low-utilization sites. Frequent staff turnover was reported by some as a barrier to the continuity of 
care necessary to ensure coordination of clozapine treatment.  
 
Another barrier was the accumulation of many small process delays, which added up to bigger 
delays for patients. At some facilities a weekly clozapine visit was an all day affair, due to delays 
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before blood draws, processing laboratory results, clinic visits and dispensing the prescription or 
limited access to transportation. Lack of coordination made it difficult to accommodate patients 
who lived far away and had difficulty getting to the medical facility on clozapine clinic days. High-
utilization sites were more flexible in terms of scheduling outside of clinic hours, offering walk in 
hours or same day appointments. 
 
Overreliance on a Few: This domain pinpoints a systems and processes issue noted at high- 
and low-utilization sites. While having committed clozapine champions was essential, it was not 
sufficient to ensure access to clozapine. Many sites relied on 1-2 clozapine champions. However, 
overreliance on too few people left sites vulnerable when staff were away due to illness, annual 
leave, or retirement. Even high-utilization sites were vulnerable in this way, though they usually 
relied on 3-4 people, rather than one or two as was the case at low-utilization sites.  
 
DISCUSSION 
We interviewed key informants at high- and low-clozapine-utilization facilities, to understand 
what specific factors prevented or facilitated clozapine-utilization. Via triangulation of key 
informant data within and across sites, we identified barriers that actually exist versus barriers 
that are only perceived Through this analysis we found that high-utilization sites had 
commonalities, among them providing access to transportation, having sufficient capacity to 
enroll patients, utilization of multidisciplinary teams including non-physician providers, better 
coordination of care, and creation of systems to reduce reliance on too few individuals. 
 
These findings suggest that clozapine clinics staffed by a multidisciplinary team, with adequate 
time to accommodate increased visit frequency and prescribing burden of clozapine, could 
improve access to evidence-based care for patients with treatment-resistant schizophrenia. This 
would include development of clozapine clinics at sites without one, and expansion of clozapine 
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clinics where one already exists. Clearly defined clinical structure and staff roles may improve 
the effectiveness of clinics.34  In addition, this study suggests that the straight forward act of 
providing transportation for patients to and from clozapine appointments has the potential to 
greatly expand the pool of patients who would be able to receive this potentially life-changing 
medication. Home visits have been a successful tool for some clozapine programs and could 
also address this issue.20 
 
There have been other similar studies using qualitative interviews of outlier sites to gain insight 
into how to organize care to achieve the best results.22,23 Some of our findings echo earlier 
studies. In particular, previous studies reported the importance of adequate staffing and 
effective integration of non-physicians into patient care are key ingredients in the success of 
programs as diverse as anticoagulation clinics and hospital teams caring for patients with acute 
coronary syndromes.22,23 In a study of clozapine patients, multi-disciplinary teams were 
associated with improved medical monitoring.35 Thus, a more effective use of multidisciplinary 
teams could improve access and outcomes across a multitude of settings. 
 
One of the strengths of this study is the focus on strategies that work well within the current 
system and rules, rather than ideas that rely on changing those rules, which may not be 
possible.20 While all of the changes or initiatives suggested by this study may be feasible (i.e. 
allowed under the rules), some of these changes would require commitment of resources. 
However, data suggest cost-savings with incremental increases in clozapine-utilization. Thus 
increased outpatient costs may be outweighed by cost-savings from reduced inpatient 
hospitalizations.36,37 In a companion study published in this issue of Psychiatric Services, we 
demonstrated incremental increases in clozapine-utilization could result in substantial cost-
savings, primarily through decreased use of inpatient admissions. Thus, implementation of 
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interventions derived from this study could more than pay for themselves, if they succeed in 
increasing clozapine-utilization for treatment-resistant schizophrenia.  
 
Patients who live far from clinics are a unique and difficult group to reach, and are not well 
served even by the highest-utilization sites studied. This means that a fairly large subset of 
patients essentially has no access to clozapine. Some of the solutions discussed above would 
help to reach this population as well. The most feasible solution would involve providing 
transportation or home-based care to patients who live far from clinics, which would admittedly 
be more expensive and laborious than providing these services to patients living closer. Some 
other solutions, like increased use of outside laboratories or point-of-care testing for blood count 
monitoring, would be difficult to implement within VA, because they may require national policy 
change. However, point-of-care testing should be considered as clozapine patients report it to 
be more convenient and less painful than traditional venipuncture.38  
  
This study does have some limitations. First, the VA limits clozapine prescribing to psychiatrists 
and neurologists. Thus some obstacles encountered in the VA may not be an issue for other 
care settings. Second, telephone interviews may be suboptimal in some cases, in part because 
of missing non-verbal cues and difficulty developing rapport. However, many of the interviews 
were much longer than anticipated, suggesting that participants felt comfortable sharing their 
experiences. Additionally, surveys of clinicians have reported similar findings.39 Thirdly, what we 
deemed high-utilization may not reflect optimal-utilization as this optimal rate has not been 
defined.  Lastly, VA sites may not be representative of other healthcare systems. However, the 
side effects, FDA REMS requirements and low-utilization for clozapine are the same inside and 
outside VA, suggesting the challenges that need to be overcome in other systems are similar to 
those faced by the sites we studied. This is true even in light of the changes to the clozapine 
REMS program, which still requires registration of physician, patient and pharmacies, frequent 
 13 
 
monitoring, and limitations on days supplied. These interventions may prove useful in other 
countries with similar monitoring requirements.  
 
In a separate study we found some relatively straightforward changes are associated with 
higher clozapine-utilization within the VA. Among these are having a dedicated clozapine clinic, 
ensuring the clinic has sufficient capacity to accommodate all patients with TRS and adequate 
levels of staffing in the clinic by non-physicians including RNs and pharmacists and providing 
transportation for appointments for clozapine patient. While all of these strategies are allowable 
under VA rules and regulations, and are currently done at some sites, they are not without cost. 
It is hoped that the present study can provide an impetus to make these relatively 
straightforward, if not inexpensive changes. Extrapolating from our findings here, an average 
sized VA site (managing 700 patients with schizophrenia) could expect to have a population of 
140 patients with TRS. Increasing the proportion of patients treated with clozapine from 20% to 
40% would save the facility greater than $625,000 in the first year. It is difficult to imagine the 
cost of implementing our recommendations could approach this figure. Thus, even a modest 
increase in clozapine-utilization, achieved at a very high cost, and could still result in a net cost 
savings for VA. 
 
CONCLUSIONS 
 Using qualitative research methods, we examined differences between VA sites that use 
clozapine at the highest and lowest rates. We found that a number of strategies already pursued 
by high-outlier sites would be feasible to implement in a broad variety of settings. These 
strategies included starting a clozapine clinic where none exists, ensuring that clozapine clinics 
have sufficient capacity to handle the number of patients for whom clozapine is indicated, 
providing transportation to all patients receiving clozapine and ensuring adequate staffing, and 
integration of non-physician clinicians within clozapine clinics. While other strategies could also 
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be considered, in many cases they would require national-level policy changes that could prove 
challenging to pursue. Used in combination, and pursued diligently, the more feasible strategies 
identified in this study would likely be sufficient to reach the goal of providing clozapine to all 
appropriate patients. 
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Table 1: Key informants by position and number of interviews 
Interviews N 
Mental health leadership  11 
Pharmacy leadership 5 
Psychiatrist  22 
Clinical pharmacist specialist 12 
Advanced practice nurse  4 
Dispensing pharmacist 9 
Laboratory staff 3 
Other* 4 
Total interviews 70 
*RN, clinic coordinator, medical technologist, social worker 
  
 21 
 
Table 2: Site Characteristics 
Facility High 
/Low 
Clozapine 
Utilization 
Rate* 
Patients with 
Schizophrenia 
Region Number of 
Interviews 
Clozapine 
Clinic 
Multi-
disciplinary 
Significant 
Transport 
Support 
A High 10% 590 Midwest 8 Yes Yes Yes 
B High 8% 1080 Northeast 7 Yes Yes Yes 
C High 15% 290 Midwest 12 Yes Yes No 
D High 10% 450 West 7 Yes Yes Yes 
E High 9% 660 Southeast 4 Yes Yes No 
F  Low 2% 550 Northeast 6 Yes Yes No 
G Low 4% 1170 West 9 Limited# Yes No 
H Low 1% 450 Southeast 8 No No Yes 
I Low 2% 1510 Southeast 6 No No No 
J Low 3% 1830 Midwest 3 No No No 
*Percentage of patients with schizophrenia receiving clozapine in 2013  
 
#Clozapine clinic was available but given limited capacity and rigidity regarding seeing patients outside of set clozapine clinic hours 
many clozapine patients were still treated by individual clinicians outside the clinic
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Table 3: Thematic Domains and Definitions  
Thematic Domain Definition 
Transportation A multifaceted issue related to the need for transportation to frequent 
medical visits. The domain was directly related to the distance to and from 
medical centers as well as the distance between community based 
outpatient clinics and major medical centers.  
Capacity Multiple reasons account for sites’ ability, or lack thereof, to prescribe 
clozapine. The domain was directly related to staffing and scheduling 
issues. 
Multidisciplinary 
care teams 
Availability and incorporation of non-physician staff impacted sites’ ability 
to initiate patients on clozapine treatment as well as to prescribe clozapine 
for patients maintained on clozapine.  
Care coordination Oversight of clozapine prescribing process was a key component in sites’ 
ability to use clozapine. The domain was related to champions, clear 
processes and ready identification of people “in charge” of clozapine. 
Over-reliance on a 
few 
Utilization of only a few people to facilitate clozapine processes left 
systems vulnerable when key personnel were away or unavailable. 
 
  
 23 
 
 
Table 4: Representative Quotes From Each  Domain 
High Utilization Site Low Utilization Site 
Transportation 
Site D: Clinical Pharmacist 
[Intensive case management staff] are 
either able to go and get them and bring 
them into clinic, or if there are residing out 
in an assisted living facility, we can 
coordinate with the facility to bring them in. 
All our [intensive case management] 
veterans do have a lot more supports in 
place to help them get into Clozaril Clinic 
without difficulty. 
Site I: Psychiatrist  
[It’s true that] not that many people like getting 
blood draws…. [But] the frequent appointments, 
the distance, a lot of people come from an hour 
away and just the logistics of coming in for 
frequent monitoring sometimes is an issue. The 
side-effects doesn't usually seem to be the factor. 
 
Capacity 
Site B: Pharmacist  
We had to tell inpatient team to stop 
referring to clozapine… because we were at 
capacity. So there were these two solutions 
– give us [staffing for] another day or we’ll 
have to start discharging patients. 
Site I: Mental Health Leadership 
People [staff] have full schedules; we are a huge 
facility and for a certain time over the past two 
years we grew up faster than we were able to 
record people and so there was time when 
people [didn’t] have a next available appointment 
for another three or four months and I think 
availability and accessibility is definitely a factor 
and this is why [we are developing a] Clozaril 
Clinic, trying to diffuse… that … barrier. 
 24 
 
 
Site C: Psychiatrist 
I have a Clozapine Clinic, on Tuesday 
morning and then, I have…quite a bit of 
overflow on Mondays and I do it as a walk-
in clinic. 
Site H: Nurse Practitioner Intensive Case 
Management  
I think it's a very effective medication.  In fact, I 
say when nothing else works, clozapine definitely 
will work, and it does keep 'em out of the 
hospital.  I don't know that we have the staff that 
can monitor  the  face-to-face follow-up that is 
really needed. 
Multi-Disciplinary Teams 
Site D: Clinical Pharmacist 
We have a number of different people in 
the clinic…we have one psychiatrist, Dr. X 
who is Head Psychiatrist over at the clinic. 
It's managed by a nurse, who keeps tabs 
on the patients who are supposed to be 
coming in for that day and prints us out a 
list of who those patients are. I serve as a 
provider in the clinic and we have another 
psychiatrist who serves as a provider and 
then when we have residents, we have 
them serve as providers for clinic. We 
meet together in the morning and we're 
given the list of patients that we'll be 
seeing for that day and then it's kind of an 
Site G: Psychiatrist 
Once we had a clinical pharmacist on board it, 
made managing patients on clozapine…and 
getting new starts much, much easier… I basically 
would recommend that every mental health, 
outpatient clinic, have a [mental health] 
pharmacist assigned to them to help manage 
[clozapine] patients. 
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open clinic so the patients show up at their 
leisure. …if I were to see a patient 
because I cannot write Clozaril orders, I 
would see the patient, do my evaluation 
and assessment and then I would [discuss 
the patient] with our chief psychiatrist and 
make my recommendations and then…[Dr. 
X] decides whether to take our 
recommendations or not and then puts in 
the orders for the patients. 
 
Care Coordination 
Site C: Clinical Pharmacist 
I think that it would be helpful to have a 
specific Clozapine clinic with providers who 
are more familiar with [clozapine]…[and 
people] who have the time to sit down with 
the patient and arrange for all of their lab 
appointments and their med renewals and 
everything…have somebody who focuses 
on that because it is time-consuming. 
There's a lot of paperwork and stuff that 
goes along with it. 
Site F: Social Worker 
I don't know that I could treat more patients…who 
are on Clozapine because it's so labor-intensive… 
I have to worry where they are and track them 
down and make sure they come in. Has a blood 
test been ordered? Are their appointments in the 
computer? Is there somebody here to draw their 
blood? I mean, there [are] so many details that 
have to be seen to…it just doesn't all happen by 
itself. 
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Site A: Pharmacist 
It worries me when … there's not somebody 
coordinating it…if we didn't have our clinic 
downstairs I don't know how any of these 
guys could stay on track. I really don't know 
how that would work.  So if there are VAs 
that don't [have a clozapine clinic], I can't 
imagine how they're doing [prescribing 
clozapine]. But maybe it's a requirement. 
Like I said… I'm not sure. 
Site G: Psychiatrist 
Monitoring patients new to clozapine is kind of 
hard to do, especially when you're busy with a 
whole bunch of other patients.  Checking to make 
[sure] their labs are okay and then writing the 
prescription every single week, I don't feel like I 
could have many patients on that kind of regime. 
Over-Reliance on a Few 
Site E: Pharmacist 
[The clinical pharmacist] is trying to do 
everything good and smooth. ..she does a 
phenomenal job.  She goes out of her way, 
she is always accessible. She leaves her 
phone number, even [when] she was out of 
country… so I can’t really tell you…how 
smooth it [would go] without her. 
 
Site G: Clinical Pharmacist 
 [The other staff]  just wait until I get back [from 
vacation]…There’ve been a couple of times when 
it’s been delayed…several days, even up to a 
week. 
 
Site A: Psychiatrist 
He does [play an integral part].  If he's not 
there and the nurse…[isn’t]  there I can 
sometimes get in his drawer and figure out 
where things are or go through the process 
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that we use [to prescribe clozapine]. 
 
